Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Combined With Chemotherapy and Endostatin in Advanced Squamous NSCLC
NCT05243355Phase 2Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in squamous cell carcinoma of the lung (SCCL), sponsored by Qilu Hospital of Shandong University. Primary endpoint: 1-Year Progression-Free Survival Rate. Status: unknown.
02
Drugs
envafolimab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05243355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243355.